title: Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins.
abstract: A series of compounds were designed and synthesized as antagonists of cIAP-1/2 and XIAP based upon our previously identified lead compound SM-122 (1). The most potent of these (7) binds to XIAP, cIAP-1, and cIAP-2 proteins with K(i) values of 36, <1, and <1.9 nM, respectively. Consistent with its potent binding affinities to IAPs, 7 effectively antagonizes XIAP in a cell-free caspase-9 functional assay, efficiently induces cIAP-1 degradation in cells at concentrations as low as 10 nM, and triggers activation of caspases and PARP cleavage in the MDA-MB-231 breast cancer cell line. Compound 7 potently inhibits cell growth in the MDA-MB-231 cancer cell line with an IC(50) value of 200 nM and is 9 times more potent than compound 1.
authors.affiliation: Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA.
authors.forename: Haiying
authors.initials: H
authors.lastname: Sun
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Lu
authors.forename: Liu
authors.initials: L
authors.lastname: Liu
authors.forename: Han
authors.initials: H
authors.lastname: Yi
authors.forename: Su
authors.initials: S
authors.lastname: Qiu
authors.forename: Chao-Yie
authors.initials: CY
authors.lastname: Yang
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Deschamps
authors.forename: Shaomeng
authors.initials: S
authors.lastname: Wang
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D053148:Caspase 3 / Q000378:metabolism; D061945:Caspase Inhibitors; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015394:Molecular Structure; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011485:Protein Binding; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D044767:Ubiquitin-Protein Ligases; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: C552335:6-(2-(methylamino)propanamido)-5-oxo-9-(2-phenylacetamido)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)decahydropyrrolo(1,2-a)azocine-3-carboxamide; D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D061945:Caspase Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D051636:X-Linked Inhibitor of Apoptosis Protein; C496866:XIAP protein, human; C494832:BIRC3 protein, human; D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D044767:Ubiquitin-Protein Ligases; D011065:Poly(ADP-ribose) Polymerases; D053148:Caspase 3; D000409:Alanine